Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$14.19
+2.8%		$13.08
$6.62
▼
$15.35
$1.33B1.27658,359 shs880,334 shs
Omeros Corporation stock logo
OMER
Omeros
$18.75
-0.2%		$12.98
$3.94
▼
$19.65
$1.36B2.62.42 million shs2.04 million shs
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$20.82
+2.9%		$25.17
$7.15
▼
$43.85
$335.60M1.48283,226 shs129,483 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$22.64
+0.7%		$20.71
$6.50
▼
$49.95
$1.33B1.71746,238 shs607,336 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-0.07%-6.88%+17.13%+49.46%+89.18%
Omeros Corporation stock logo
OMER
Omeros
+0.97%-2.74%+58.70%+83.14%+351.68%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-1.03%-1.22%-16.26%-17.15%+136.15%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-0.75%-1.01%+6.29%+64.57%-42.94%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$14.19
+2.8%		$13.08
$6.62
▼
$15.35
$1.33B1.27658,359 shs880,334 shs
Omeros Corporation stock logo
OMER
Omeros
$18.75
-0.2%		$12.98
$3.94
▼
$19.65
$1.36B2.62.42 million shs2.04 million shs
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$20.82
+2.9%		$25.17
$7.15
▼
$43.85
$335.60M1.48283,226 shs129,483 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$22.64
+0.7%		$20.71
$6.50
▼
$49.95
$1.33B1.71746,238 shs607,336 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-0.07%-6.88%+17.13%+49.46%+89.18%
Omeros Corporation stock logo
OMER
Omeros
+0.97%-2.74%+58.70%+83.14%+351.68%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-1.03%-1.22%-16.26%-17.15%+136.15%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-0.75%-1.01%+6.29%+64.57%-42.94%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
3.00
Buy$26.1784.40% Upside
Omeros Corporation stock logo
OMER
Omeros
2.67
Moderate Buy$38.00102.67% Upside
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
3.00
Buy$47.30127.19% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.82
Moderate Buy$43.3891.59% Upside

Current Analyst Ratings Breakdown

Latest STRO, OMER, VOR, and MGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$26.00 ➝ $27.00
8/13/2026
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/13/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/13/2026
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetMarket Outperform$41.00 ➝ $34.00
8/13/2026
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$60.00
8/12/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$18.00 ➝ $27.00
8/11/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D+)
8/7/2026
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$48.00
8/5/2026
Omeros Corporation stock logo
OMER
Omeros
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
8/5/2026
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/27/2026
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$81.39M16.74N/AN/A$2.25 per share6.31
Omeros Corporation stock logo
OMER
Omeros
N/AN/A$1.87 per share10.04($0.71) per shareN/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$102.48M3.37N/AN/A($6.23) per share-3.34
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$114.20M$0.7119.99N/AN/A19.87%283.85%29.39%11/12/2026 (Estimated)
Omeros Corporation stock logo
OMER
Omeros
-$3.35M$1.2814.6516.59N/AN/A-164.92%69.41%11/12/2026 (Estimated)
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$191.09M-$11.97N/AN/AN/A-395.25%N/A-88.12%11/5/2026 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest STRO, OMER, VOR, and MGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.4583$1.71+$2.1683$1.71$0.70 million$321.43 million
8/13/2026Q2 2026
Omeros Corporation stock logo
OMER
Omeros
-$0.2683$0.02+$0.2883$0.15$12.69 million$28.53 million
8/12/2026Q2 2026
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$2.19-$2.33-$0.14-$2.33$11.96 million$9.84 million
8/11/2026Q2 2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-$0.69-$0.80-$0.11-$1.16N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/AN/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.46
3.76
3.76
Omeros Corporation stock logo
OMER
Omeros
N/A
1.95
1.94
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/A
3.32
3.32
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
Omeros Corporation stock logo
OMER
Omeros
48.79%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
96.99%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.40%
Omeros Corporation stock logo
OMER
Omeros
10.50%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
1.80%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30096.04 million88.94 millionOptionable
Omeros Corporation stock logo
OMER
Omeros
21072.39 million64.79 millionOptionable
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
24016.58 million16.28 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
14059.16 million59.00 millionN/A

Recent News About These Companies

Vor Bio To Participate in Upcoming September Conferences
September 1 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354086/0/en/vor-bio-to-participate-in-upcoming-september-conferences.html
Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-vor-biopharma-nasdaqvor-to-hold-2026-08-15/
Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/q3-eps-estimates-for-vor-biopharma-reduced-by-hc-wainwright-2026-08-14/
Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-fy2030-eps-forecast-reduced-by-hc-wainwright-2026-08-13/
Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wedbush-issues-positive-forecast-for-vor-biopharma-nasdaqvor-stock-price-2026-08-12/
Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-nasdaqvor-trading-down-65-on-disappointing-earnings-2026-08-12/
Vor Biopharma Shares Drop After Q2 Results
August 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vor-biopharma-shares-drop-q2-140534024.html
Vor Biopharma (NASDAQ:VOR) Posts Earnings Results
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-nasdaqvor-posts-earnings-results-2026-08-11/
Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69277816-vor-biopharma-vor-bio-reports-second-quarter-2026-financial-results-and-provides-corporate-update-399.htm
Renaissance Technologies LLC Makes New $2.30 Million Investment in Vor Biopharma Inc. $VOR
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-makes-new-230-million-investment-in-vor-biopharma-inc-vor-2026-08-11/
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Analysts
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vor-biopharma-inc-nasdaqvor-receives-consensus-rating-of-moderate-buy-from-analysts-2026-08-09/
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/03/3337912/0/en/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors
July 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/68970529-vor-biopharma-vor-bio-appoints-david-zaccardelli-to-board-of-directors-399.htm
Vor Bio Appoints David Zaccardelli to Board of Directors
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323613/0/en/vor-bio-appoints-david-zaccardelli-to-board-of-directors.html
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes
July 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4920412-vor-biopharma-a-financed-autoimmune-pivot-with-more-substance-than-the-market-realizes
Vor Biopharma Stock Short Interest Report | NASDAQ:VOR | Benzinga
July 3, 2026  |  benzinga.comhttps://www.benzinga.com/quote/VOR/short-interest
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/02/3321604/0/en/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next
June 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/why-vor-biopharma-vor-24-150826972.html
Vor Biopharma: Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
June 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68709300-vor-biopharma-telitacicept-receives-nmpa-conditional-approval-for-the-treatment-of-iga-nephropathy-in-china-399.htm
Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China
June 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/08/3308123/0/en/telitacicept-receives-nmpa-approval-for-the-treatment-of-sj%c3%b6gren-s-disease-in-china.html
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
June 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/08/3308115/0/en/telitacicept-receives-nmpa-conditional-approval-for-the-treatment-of-iga-nephropathy-in-china.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo displayed on a computer chip surrounded by illuminated green circuit board traces.
NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
By Thomas Hughes | August 11, 2026
Trading floor with digital stock displays and workstations, overlaid with the text "S&P 500".
5 Reasons the S&P 500 Could Keep Rallying Through Year-End
By Thomas Hughes | August 20, 2026
AMD logo centered on a glowing semiconductor chip with illuminated circuitry, symbolizing AI GPUs and surging demand in the semiconductor industry.
AMD’s Post-Earnings Drop May Be the Opportunity Investors Wanted
By Thomas Hughes | August 5, 2026
Palantir logo displayed over a digital globe with glowing network connections in a control room setting.
Palantir Soars 30% After Blockbuster Earnings—Is the Rally Just Getting Started?
By Chris Markoch | August 5, 2026
MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$14.19 +0.38 (+2.75%)
As of 04:00 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Omeros stock logo

Omeros NASDAQ:OMER

$18.75 -0.04 (-0.21%)
As of 04:00 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Sutro Biopharma stock logo

Sutro Biopharma NASDAQ:STRO

$20.82 +0.58 (+2.87%)
As of 04:00 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Vor Biopharma stock logo

Vor Biopharma NASDAQ:VOR

$22.64 +0.16 (+0.71%)
As of 04:00 PM Eastern

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas